RT Journal Article
T1 Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain
A1 Majem, Margarita
A1 Alvarez, Rosa
A1 Laura Ortega, Ana
A1 Ruiz de Alda, Lucia
A1 Gordo, Rocio
A1 Francisco Garcia, J.
A1 Ivanova-Markova, Yoana
A1 Gonzalez-Dominguez, Almudena
A1 Sanchez San Cristobal, Raquel
A1 Rojo, Federico
K1 ALK
K1 Cost -benefit
K1 Cost-effectiveness
K1 Economic evaluation
K1 Lung cancer
K1 Non-small cell lung cancer
K1 Care
AB Introduction: In recent years, target therapies to specific molecular alterations in advanced non-small cell lung cancer (NSCLC) have been identified and have shown superior efficacy compared to non-targeted treatments. Anaplastic lymphoma kinase (ALK) is one of the therapeutic targets; nevertheless, ALK diagnosis is not performed in all NSCLC patients in Spain. The objective of this study is to estimate in monetary terms the benefit for the Spanish society of ALK diagnosis in advanced NSCLC patients.Methods: A cost-benefit analysis of ALK diagnosis vs. non-diagnosis in advanced NSCLC patients was carried out from the Spanish social perspective, with a time horizon of 5 years. Costs, benefits and the cost-benefit ratio were measured. The analysis has considered the overall survival in advanced NSCLC patients treated with the ALKtyrosine kinase inhibitor (TKI) alectinib. The natural history of NSCLC was simulated using a Markov model. A 3% discount rate was applied to both costs and benefits. The result was tested using a deterministic sensitivity analysis.Results: The cost of ALK diagnosis vs. non-diagnosis in the base case would be euro 10.19 million, generating benefits of euro 11.71 million. The cost-benefit ratio would be euro 1.15. In the sensitivity analysis, the cost-benefit ratio could range from euro 0.89 to euro 2.10.Conclusions: The results justify the universal application of ALK diagnosis in advanced NSCLC, which generates a benefit for Spanish society that outweighs its costs and allows optimal treatment with targeted therapies for these patients.
PB Aboutscience srl
SN 2284-2403
YR 2022
FD 2022-09-12
LK http://hdl.handle.net/10668/21814
UL http://hdl.handle.net/10668/21814
LA en
DS RISalud
RD Apr 8, 2025